Top Markets
Coin of the day
OncoCyte Corporation OncoCyte Corporation

OncoCyte Corporation

OCX
Rang in aandelen #38932
OncoCyte Corporation is a molecular diagnostics firm that conceptualizes,... OncoCyte Corporation is a molecular diagnostics firm that conceptualizes, refines, and brings to market its exclusive laboratory-developed tests aimed at identifying cancer in patients, serving both the United States and global markets. The company's portfolio features DetermaRx, a specialized molecular test for detecting early-stage adenocarcinoma in the lung, alongside DetermaIO, a unique proprietary assay that assesses gene expression. In addition to its diagnostic offerings, OncoCyte provides a suite of services including biomarker discovery, the design and development of new assays, and essential support for clinical trials. It also delivers various biomarker testing solutions specifically tailored for pharmaceutical companies. OncoCyte has established a collaborative agreement with Life Technologies Corporation. This partnership is geared towards the co-development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, which are designed for use with the Ion Torrent Genexus integrated sequencer and purification system. The corporation was founded in 2009 and its primary base of operations is situated in Irvine, California.
Aandeelprijs
$2.84
Laatst gesynchroniseerd: 2025-07-14
Marktkapitalisatie
$729.71K
Verandering (1 dag)
-0.70%
Verandering (1 jaar)
0.00%
Land
US
Handel OncoCyte Corporation (OCX)

Categorie

EPS voor OncoCyte Corporation (OCX)
EPS per 2026 TTM: 0
Volgens de laatste financiële rapporten en de aandelenkoers van OncoCyte Corporation is de huidige EPS van het bedrijf (TTM) 0. Eind 2026 had het bedrijf een EPS van 0, gelijk aan de EPS van 2026 die 0 bedroeg.
EPS-geschiedenis van OncoCyte Corporation van 2026 tot 2026
EPS aan het einde van elk jaar
Jaar EPS Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
EPS van vergelijkbare bedrijven of concurrenten